Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers
Abstract Nanocarrier systems are widely used for drug delivery applications, but limitations such as the use of synthetic surfactants, leakage of toxic drugs, and a poor encapsulation capacity remain as challenges. We present a new hybrid nanocarrier system that utilizes natural materials to overcom...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2023-09-01
|
| Series: | Discover Nano |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s11671-023-03897-3 |
| _version_ | 1797451751889043456 |
|---|---|
| author | Sedef Salel Banu Iyisan |
| author_facet | Sedef Salel Banu Iyisan |
| author_sort | Sedef Salel |
| collection | DOAJ |
| description | Abstract Nanocarrier systems are widely used for drug delivery applications, but limitations such as the use of synthetic surfactants, leakage of toxic drugs, and a poor encapsulation capacity remain as challenges. We present a new hybrid nanocarrier system that utilizes natural materials to overcome these limitations and improve the safety and efficacy of drug delivery. The system comprises a biopolymeric shell and a lipid core, encapsulating the lipophilic anticancer drug paclitaxel. Bovine serum albumin and dextran, in various molecular weights, are covalently conjugated via Maillard reaction to form the shell which serves as a stabilizer to maintain nanoparticle integrity. The properties of the system, such as Maillard conjugate concentration, protein/polysaccharide molar ratio, and polysaccharide molecular weight, are optimized to enhance nanoparticle size and stability. The system shows high stability at different pH conditions, high drug loading capacity, and effective in vitro drug release through the trigger of enzymes and passive diffusion. Serine proteases are used to digest the protein portion of the nanoparticle shell to enhance the drug release. This nanocarrier system represents a significant advancement in the field of nanomedicine, offering a safe and effective alternative for the delivery of lipophilic drugs. Graphical abstract |
| first_indexed | 2024-03-09T14:58:58Z |
| format | Article |
| id | doaj.art-52e0ca2ac2c74aa3aca8a9734f72c945 |
| institution | Directory Open Access Journal |
| issn | 2731-9229 |
| language | English |
| last_indexed | 2024-03-09T14:58:58Z |
| publishDate | 2023-09-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Nano |
| spelling | doaj.art-52e0ca2ac2c74aa3aca8a9734f72c9452023-11-26T14:01:25ZengSpringerDiscover Nano2731-92292023-09-0118111210.1186/s11671-023-03897-3Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriersSedef Salel0Banu Iyisan1Biofunctional Nanomaterials Design (BiND) Laboratory, Institute of Biomedical Engineering, Bogazici UniversityBiofunctional Nanomaterials Design (BiND) Laboratory, Institute of Biomedical Engineering, Bogazici UniversityAbstract Nanocarrier systems are widely used for drug delivery applications, but limitations such as the use of synthetic surfactants, leakage of toxic drugs, and a poor encapsulation capacity remain as challenges. We present a new hybrid nanocarrier system that utilizes natural materials to overcome these limitations and improve the safety and efficacy of drug delivery. The system comprises a biopolymeric shell and a lipid core, encapsulating the lipophilic anticancer drug paclitaxel. Bovine serum albumin and dextran, in various molecular weights, are covalently conjugated via Maillard reaction to form the shell which serves as a stabilizer to maintain nanoparticle integrity. The properties of the system, such as Maillard conjugate concentration, protein/polysaccharide molar ratio, and polysaccharide molecular weight, are optimized to enhance nanoparticle size and stability. The system shows high stability at different pH conditions, high drug loading capacity, and effective in vitro drug release through the trigger of enzymes and passive diffusion. Serine proteases are used to digest the protein portion of the nanoparticle shell to enhance the drug release. This nanocarrier system represents a significant advancement in the field of nanomedicine, offering a safe and effective alternative for the delivery of lipophilic drugs. Graphical abstracthttps://doi.org/10.1186/s11671-023-03897-3Drug delivery systemsHybrid nanoparticlesProtein/polysaccharide conjugates |
| spellingShingle | Sedef Salel Banu Iyisan Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers Discover Nano Drug delivery systems Hybrid nanoparticles Protein/polysaccharide conjugates |
| title | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
| title_full | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
| title_fullStr | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
| title_full_unstemmed | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
| title_short | Polymer–lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
| title_sort | polymer lipid hybrid nanoparticles as potential lipophilic anticancer drug carriers |
| topic | Drug delivery systems Hybrid nanoparticles Protein/polysaccharide conjugates |
| url | https://doi.org/10.1186/s11671-023-03897-3 |
| work_keys_str_mv | AT sedefsalel polymerlipidhybridnanoparticlesaspotentiallipophilicanticancerdrugcarriers AT banuiyisan polymerlipidhybridnanoparticlesaspotentiallipophilicanticancerdrugcarriers |